Cancer channel
The latest news, views and analysis from the pharmaceutical industry’s frontline in the war on cancer. Updates on pharmaceutical and biotech oncology pipelines, regulatory decisions and market access news, and how healthcare systems needs to change to tackle one of the world’s biggest killers.
Bayer and MD Anderson collaborate on novel targeted cancer treatments
Bayer and the University of Texas MD Anderson Cancer Center have signed a five-year collaboration agreement to accelerate the development of novel targeted treatments for cancer.
New data boosts Roche lung cancer combo
More positive results from Tecentriq, Avastin and chemo combo
AbbVie’s shares tank after cancer hopeful’s phase 2 setback
Decision wipes $24 billion from share price
Autolus’ solid tumour CAR-Ts will have ‘off switch’
Up and coming immunotherapy company Autolus has published details of an ‘off switch’ safety features in its next generation CAR-Ts.
Adaptimmune and GSK’s novel T-cell therapy works in solid tumours
Adaptimmune has more good news from its SPEAR T-cell therapy, yesterday unveiling encouraging early results in four patients with myxoid/round cell liposarcoma (MRCLS).
Genomics pioneer Sir John Sulston dies
One of the world’s foremost scientist and pioneer of genomics, Professor Sir John Sulston has died at the age of 75.
MSD launches first Herceptin biosimilar in UK
Ontruzant, the first biosimilar version of Roche’s Herceptin (trastuzumab) in Europe has been launched in the UK by MSD.
Breath Biopsy company adds new investor to $15m fundraising
Owlstone Medical, the innovative company which promises to revolutionise the diagnosis of cancer by simply analysing a patient’s breath has been given a major funding boost.
AI specialists join Genomics England’s drug discovery alliance
Lantern Pharma, a pharma company which uses artificial intelligence to develop shelved oncology drugs has joined Genomics England’s groundbreaking industry partnership.
Bluebird bio details plans to file three blockbusters
Biotech looks to take on Novartis, Gilead, and Juno in CAR-T
